These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 13901859)

  • 1. A comparison of blood levels after oral administration of erythromycin and erythromycin estolate.
    GRIFFITH RS; BLACK HR
    Antibiot Chemother (Northfield); 1962 Jun; 12():398-403. PubMed ID: 13901859
    [No Abstract]   [Full Text] [Related]  

  • 2. Concentrations of erythromycin in serum and tonsil: comparison of the estolate and ethyl succinate suspensions.
    Ginsburg CM; McCracken GH; Culbertson MC
    J Pediatr; 1976 Dec; 89(6):1011-3. PubMed ID: 792404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography.
    Croteau D; Bergeron MG; LeBel M
    Antimicrob Agents Chemother; 1988 Apr; 32(4):561-5. PubMed ID: 3259856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-benefit equation for erythromycin estolate.
    LeBel M
    Am J Hosp Pharm; 1980 Feb; 37(2):176, 180. PubMed ID: 7361788
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma bactericidal activity after administration of erythromycin estolate and erythromycin ethylsuccinate to healthy volunteers.
    Bérubé D; Kirouac D; Croteau D; Bergeron MG; Lebel M
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1227-30. PubMed ID: 3142349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of erythromycin ethylsuccinate and estolate in infants under 4 months of age.
    Patamasucon P; Kaojarern S; Kusmiesz H; Nelson JD
    Antimicrob Agents Chemother; 1981 May; 19(5):736-9. PubMed ID: 6975059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.
    Welling PG; Elliott RL; Pitterle ME; Corrick-West HP; Lyons LL
    J Pharm Sci; 1979 Feb; 68(2):150-5. PubMed ID: 423080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals.
    Lakritz J; Wilson WD; Marsh AE; Mihalyi JE
    Am J Vet Res; 2000 Aug; 61(8):914-9. PubMed ID: 10951982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioautography of erythromycin and its esters.
    Easterbrook SM; Hersey JA
    J Chromatogr; 1976 Jun; 121(2):390-4. PubMed ID: 932154
    [No Abstract]   [Full Text] [Related]  

  • 10. Fluorometric determination of erythromycin and erythromycin propionate in whole blood or plasma and correlation of results with microbiological assay.
    Tserng KY; Wagner JG
    Anal Chem; 1976 Feb; 48(2):348-53. PubMed ID: 1247163
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of erythromycin base and estolate in gonococcal urethritis.
    Brown ST; Pedersen HB; Holmes KK
    JAMA; 1977 Sep; 238(13):1371-3. PubMed ID: 408522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of an oral erythromycin product.
    Fraser DG
    Am J Hosp Pharm; 1980 Sep; 37(9):1199-205. PubMed ID: 6998290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate.
    Keeffe EB; Reis TC; Berland JE
    Dig Dis Sci; 1982 Aug; 27(8):701-4. PubMed ID: 6980110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of inclusion conjunctivitis after oral erythromycin therapy.
    Laperrière H; Lefebvre J
    CMAJ; 1988 Nov; 139(9):875. PubMed ID: 3179892
    [No Abstract]   [Full Text] [Related]  

  • 15. Erythromycin jaundice: diagnosis by an in vitro challenge test.
    Cooksley WG; Powell LW
    Aust N Z J Med; 1977 Jun; 7(3):291-3. PubMed ID: 269690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative bioavailability evaluation of erythromycin base and its salts and esters. I. Erythromycin estolate capsules versus enteric-coated erythromycin base tablets.
    DiSanto AR; Tserng KY; Chodos DJ; DeSante KA; Albert KS; Wagner JG
    J Clin Pharmacol; 1980 Jul; 20(7):437-43. PubMed ID: 7430412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of antimicrobial activity of erythromycin estolate and demethylchlortetracycline against hemolytic streptococci.
    GRIFFITH RS; BLACK HR
    Antibiot Chemother (Northfield); 1962 Jun; 12():353-9. PubMed ID: 13901860
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythromycin estolate impairs the mitochondrial and microsomal calcium homeostasis: correlation with hepatotoxicity.
    Richelmi P; Baldi C; Manzo L; Berte F; Martino AP; Mirabelli F; Bellomo G
    Arch Toxicol Suppl; 1984; 7():298-302. PubMed ID: 6595996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythromycin estolate to remain on market.
    FDA Drug Bull; 1982 Aug; 12(2):14. PubMed ID: 7141171
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA begins proceedings to remove erythromycin estolate from market.
    FDA Drug Bull; 1979 Nov; 9(5):26-7. PubMed ID: 510836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.